Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HRD Cancer”

96 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 96 results

Testing effectiveness (Phase 2)UnknownNCT05201612
What this trial is testing

Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

Who this might be right for
Metastatic Colorectal Cancer
Grupo Espanol Multidisciplinario del Cancer Digestivo 40
Testing effectiveness (Phase 2)Study completedNCT02952534
What this trial is testing

Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
pharmaand GmbH 277
Not applicableUnknownNCT04651933
What this trial is testing

A Training Set for the HRD Model in EOC

Who this might be right for
Epithelial Ovarian CancerBRCA MutationLoss of Heterozygosity+3 more
Lei Li 200
Testing effectiveness (Phase 2)Study completedNCT02789332
What this trial is testing

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

Who this might be right for
Breast CancerTriple Negative Breast NeoplasmsHRpos Breast Neoplasms+1 more
GBG Forschungs GmbH 107
Testing effectiveness (Phase 2)Active Not RecruitingNCT03742895
What this trial is testing

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Who this might be right for
Advanced Solid Neoplasms
Merck Sharp & Dohme LLC 326
Testing effectiveness (Phase 2)Ended earlyNCT04718675
What this trial is testing

KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Who this might be right for
Relapsed Solid TumorsRefractory Solid TumorsNon-Hodgkin Lymphoma+2 more
Kronos Bio 135
Testing effectiveness (Phase 2)Looking for participantsNCT04503265
What this trial is testing

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Who this might be right for
Advanced Malignant NeoplasmBreast CancerOvarian Cancer+3 more
AtlasMedx, Incorporated 122
Testing effectiveness (Phase 2)Study completedNCT02983799
What this trial is testing

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 272
Not applicableStudy completedNCT04651920
What this trial is testing

A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerChineseHomologous Recombination Deficiency+4 more
Lei Li 240
Testing effectiveness (Phase 2)UnknownNCT05732129
What this trial is testing

The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.

Who this might be right for
Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer
Fudan University 29
Testing effectiveness (Phase 2)UnknownNCT04499118
What this trial is testing

AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer

Who this might be right for
HER2-negative Breast Cancer
Sichuan Provincial People's Hospital 100
Large-scale testing (Phase 3)Looking for participantsNCT06954584
What this trial is testing

Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Tongji Hospital 424
Large-scale testing (Phase 3)Ended earlyNCT00448266
What this trial is testing

Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD

Who this might be right for
Breast Cancer
The Netherlands Cancer Institute 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07113964
What this trial is testing

QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

Who this might be right for
Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
The First Affiliated Hospital with Nanjing Medical University 79
Testing effectiveness (Phase 2)Looking for participantsNCT04515836
What this trial is testing

Olaparib in Patients With HRD Malignant Mesothelioma

Who this might be right for
MesotheliomaHomologous Recombination Deficiency
University of Chicago 56
Testing effectiveness (Phase 2)Ended earlyNCT03712930
What this trial is testing

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)Homologous Recombination Deficiency (HRD)
BeiGene 13
Early research (Phase 1)Active Not RecruitingNCT00777582
What this trial is testing

Phase I Comparative Bioavailability Study

Who this might be right for
Solid Tumors
AstraZeneca 197
Testing effectiveness (Phase 2)Looking for participantsNCT04826341
What this trial is testing

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Who this might be right for
HRD CancerSCLCAdvanced Solid Tumors
National Cancer Institute (NCI) 120
Large-scale testing (Phase 3)Active Not RecruitingNCT03522246
What this trial is testing

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Who this might be right for
Epithelial Ovarian CancerPrimary PeritonealFallopian Tube Cancer+4 more
pharmaand GmbH 1,097
Testing effectiveness (Phase 2)WithdrawnNCT04895046
What this trial is testing

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Who this might be right for
HRDCholangiocarcinomaMetastatic Cancer
Walid Shaib, MD
Load More Results